Summary of the Conference Call for Haijia Medical Company Overview - **Company**: Haijia Medical - **Industry**: Healthcare Services Key Points Financial Performance - In 2025, operating cash flow is expected to grow by 34.4% year-on-year to RMB 9.5 billion, driven by increased revenue from self-paid services and improved collection efficiency with accounts receivable down by 16.6% [2][3] - Inventory turnover efficiency improved by over 10% [2] - Depreciation and amortization is approximately RMB 310 million, indicating a strong cash return phase [2] - The company has a maximum capacity of 14,000 beds, sufficient to support five years of development with no new hospital construction plans in the short term [2][3] Capital Allocation and Shareholder Returns - The company plans to execute a RMB 300 million share buyback and intends to cancel the repurchased shares [2][9] - There is a focus on reducing interest-bearing debt and exploring quality domestic and international acquisitions [2][3] - Expected normalized free cash flow post the opening of Changshu Hospital in late 2026 is projected to reach RMB 800-900 million [2] Growth Areas - International medical and innovative business segments are emerging growth drivers, with Chongqing Hospital's international department generating over RMB 8 million in revenue in December 2025 [2][4] - The brain-computer interface business is expected to generate annual revenue of approximately RMB 250-260 million, with a dedicated division established in 2026 [2][11] M&A and Goodwill Impairment - The goodwill impairment related to Suzhou Yongding Hospital was due to high initial market valuations and changes in the macro environment, but the hospital's operations are currently stable [7] - Other acquired hospitals show no impairment pressure, indicating strong operational management capabilities [7] Response to Industry Changes - The company emphasizes a "patient-first" culture and has seen patient visits reach 4.6 million in 2025, with a five-year compound growth rate of 35% [5][6] - Continuous investment in talent and technology, with 108 national-level professionals and 907 senior professionals by 2025 [6] - The company is focusing on refined management practices to enhance operational efficiency [6] Market Outlook and Strategy - The company is optimistic about the long-term healthcare demand driven by aging demographics, despite short-term policy uncertainties [5][14] - Plans to leverage the long-term care insurance policy to tap into the growing demand for integrated medical and nursing services [8][16] AI Integration - AI is being integrated into management and service efficiency, with applications in supply chain and administrative management [13] - The company has developed an AI customer service system to enhance patient interaction and satisfaction [13] Future Projections - The company expects to achieve breakeven cash flow for the Texas Hospital by the end of 2026, with Wuxi Hospital anticipated to connect to medical insurance by March-April 2026 [9] - Long-term growth is expected for Chang'an Hospital, with multiple growth points identified in critical care and oncology [17] Valuation Perspective - The company's value is considered significantly undervalued, with approximately RMB 800 million in free cash flow and a focus on long-term cash flow stability [18] Additional Insights - The company maintains a cautious approach to overseas acquisitions, focusing on smaller projects initially while prioritizing domestic growth opportunities [16] - The operational efficiency and strategic management are seen as key competitive advantages in a changing healthcare landscape [16]

Core Insights - The seminar focused on "senior pet health," addressing the increasing health issues faced by aging pets as the first batch of domestic pets reaches old age [2][5][36] - Experts from various fields discussed critical topics such as tumor prevention and treatment, obesity management, infectious disease control, and the application of genetic testing technologies [3][4] Aging Pet Health Issues - Data indicates that over 50% of senior dogs and more than 30% of senior cats are diagnosed with tumors, with cancer being the leading cause of death among aging pets [6][7] - In the U.S., approximately 6 million pets die from cancer each year, highlighting the severity of the issue [7] Tumor Diagnosis and Treatment - The incidence of pet tumors is on the rise, with many cases diagnosed at advanced stages, making treatment challenging [10] - Early detection is crucial for improving treatment outcomes, with current diagnostic methods including cytology, pathology, and advanced imaging techniques [11][12] - The overall cure rate for pet cancer is about 45%, with surgery accounting for 22%, radiation for 18%, and chemotherapy for 5% [14] Obesity and Health Risks - Obesity in pets is linked to various health issues, including arthritis, diabetes, cardiovascular diseases, and is associated with 25%-30% of cancer cases [19] - The phenomenon of pets mirroring their owners' body types is common, often due to owners' lack of self-discipline in feeding [16][17] Infectious Disease Control - The protection offered by routine vaccinations for senior pets needs regular evaluation, particularly concerning viral diseases related to tumors [24] - There is a need for enhanced local epidemiological research due to differences in disease prevalence domestically and internationally [25] Genetic Testing Innovations - Genetic testing technology offers a breakthrough in managing the health of aging pets by detecting tumor risks earlier than traditional imaging methods [29][30] - A three-tier risk assessment system (high, medium, low) is established based on free DNA in the blood, although further clinical validation is required [31][32] Systematic Health Management Approach - The industry consensus emphasizes the need for a systematic approach to senior pet health management, including regular check-ups, early screening, and comprehensive interventions [34] - Tumors pose a significant health threat, necessitating enhanced early diagnosis and integrated treatment strategies [35]